It is estimated that 4.2% of the U.S. population is dependent on marijuana. Among those seeking treatment for their marijuana use, only a small percentage are able to achieve abstinence. During our previous funding period, we developed a laboratory model that identified medications that attenuate symptoms of marijuana withdrawal. The objective of this competing continuation is to refine our model to predict medications that decrease relapse to marijuana use, defined as the resumption of marijuana smoking after a period of abstinence. The underlying assumption of this proposal is that 1) dependence and withdrawal play a role in maintaining frequent marijuana use, and 2) attenuating either marijuana withdrawal or marijuana's positive reinforcing effects will decrease relapse.
Aim #1. Develop a laboratory model of marijuana relapse. We hypothesize that abstinence will: (1) increase symptoms of withdrawal, (2) decrease the latency to self-administer marijuana, (3) increase the quantity of marijuana self-administered.
Aim #2. Evaluate the ability of pharmacological interventions to decrease marijuana relapse by attenuating symptoms of marijuana withdrawal. Using this model, we will evaluate oral THC and nefazodone, which we have shown decrease symptoms of marijuana withdrawal. We hypothesize that both oral THC and nefazodone will: (1) dose-dependently increase the latency to self-administer marijuana, and (2) thus, dose-dependently decrease the quantity of marijuana self-administered following a period of marijuana abstinence.
Aim #3. Evaluate the ability of pharmacological interventions to decrease marijuana use by attenuating marijuana's direct effects. We will evaluate the cannabinoid receptor antagonist, SR141716A. We hypothesize that SR will dose-dependently decrease the quantity of marijuana self-administered following a period of marijuana abstinence. Little is known about the factors contributing to the high relapse rates in marijuana treatment-seekers. The strength of this protocol lies in our utilization of a controlled laboratory setting to examine the interactive effects of medications on marijuana self-administration under conditions that model relapse. The data collected will provide information on the positive and negative reinforcing factors maintaining near-daily marijuana use, and will suggest more efficacious approaches to treating marijuana dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009236-12
Application #
7072736
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
12
Fiscal Year
2005
Total Cost
$288,355
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Brezing, Christina A; Choi, C Jean; Pavlicova, Martina et al. (2018) Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict 27:101-107
Cooper, Ziva D; Bedi, Gillinder; Ramesh, Divya et al. (2018) Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 43:2046-2055
Chao, Thomas; Radoncic, Vanya; Hien, Denise et al. (2018) Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory. Drug Alcohol Depend 185:23-32
Metz, Verena E; Sullivan, Maria A; Jones, Jermaine D et al. (2017) Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs 49:59-68
Metz, Verena E; Jones, Jermaine D; Manubay, Jeanne et al. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:1825-1832
Vadhan, Nehal P; Corcoran, Cheryl M; Bedi, Gill et al. (2017) Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res 257:372-374
Bachtell, Ryan K; Jones, Jermaine D; Heinzerling, Keith G et al. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend 180:156-170
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Cooper, Ziva D; Johnson, Kirk W; Pavlicova, Martina et al. (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 21:895-903
Herrmann, Evan S; Cooper, Ziva D; Bedi, Gillinder et al. (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) 233:2469-78

Showing the most recent 10 out of 129 publications